Welcome address
Chairs: P. Christopoulos, F. Koinis (GR)
09.00-09.30 Transforming the standard of adjuvant NSCLC treatment A. Kotsakis (GR) Sponsored by ROCHE
09.30-10.00 The emerging relevance of neo-adjuvant immunotherapy in early NSCLC D. Papadatos-Pastos (UK)
10.00-10.30 The landscape of front-line immunotherapy in advanced/metastatic NSCLC D. Ziogas (GR)
10.30-11.00 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)
Coffee Break
Chairs: S. Gennatas (UK), F.I. Dimitrakopoulos (GR)
11.30-12.00 Bi-Specific Agents for immunotherapy in lung cancer F. Koinis (GR)
12.00-12.30 Advances in the antibody drug conjugates therapeutic strategies in lung cancer K. Boleti (UK)
12.30-13.00 Therapeutic Potential of Tumour Infiltrating Lymphocytes (TILs) in lung cancer V. Tseveleki (GR)
Chairs: K. Kosmatopoulos (FR), A. Giatromanolaki (GR)
13.00-13.15 A fish in the service of clinical decision making G. Evangelou (GR)
13.15-13.30 Improved monitoring of ALK+ lung cancer using circulating DNA analysis P. Christopoulos (DE)
13.30-13.45 Combinatorial molecular and immunological biomarkers for immunotherapy response in NSCLC patients. A. Xagara (GR)
13.45-14.00 Management of CNS metastases in NSCLC G. Tsakonas (SE)
14.00-14.15 Towards efficient cancer immunotherapies: deciphering the landscape of antigen-presenting cells Μ. Tsoumakidou (GR)
Light Lunch
Chairs: A. Kotsakis (GR), S. Fortis (GR)
15.00-15.30 Novel mechanisms in immune checkpoint inhibitor resistance P. Verginis (GR)
15.30-16.00 DNA Damage Response (DDR) gene mutations and HRD status: Are they new emerging biomarkers for the treatment of Thoracic Tumors Th. Rampias (GR)
16.00-16.30 Patient-derived organoids for precision lung cancer immunotherapy M. Tsoumakidou (GR)
Chairs: A. Boleti (UK), F. Papageorgiou (GR)
16.30-17.00 The biologic and clinical relevance of CTCs in Lung Cancer E. Lianidou (GR)
17.00-17.30 The relevance of ctDNA for the detection of Minimal Residual Disease in NSCLC Ch. Abbosh (UK)
17.30-18.00 Value of ctDNA for the monitoring of treatment efficacy in advanced/metastatic NSCLC P. Savvides (US)
Coffee Break
Chairs: P. Foukas (GR), M. Tsoumakidou (GR)
18.20-18.35 Messenger-RNA expression of BRCA1, RRM1, RRM2, hENT1, dCK and CDA genes predicting outcome to gemcitabine-based chemotherapy in advanced-stage NSCLC G. Ioannidis (CY)
18.35-18.50 Clinical significance of Patras Immunotherapy Score (PIOS) in NSCLC Ι. Pyrousis (GR)
18.50-19.05 Collaborative Project on Lung G. Skoulidis (US)
19.05-19.20 Tumor Microenvironment and Immune Response in Lung Cancer M. Koukourakis (GR)
Chairs: A. Klinakis (GR), M. Rovithi (GR)
Machine learning in systems approaches for lung cancer V. Megalooikonomou (GR)
Chairs: A. Kotsakis (GR), Ε. Sarris (GR)
09.00-09.30 Targeting KRAS-Driven NSCLC P. Economopoulou (GR)
09.30-10.00 Current treatment and perspectives in common EGFR-mutated NSCLC A. Georgiou (UK)
10.00-10.30 Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC P. Christopoulos (DE)
Coffee Break
Moderators: G.Tsakonas (SE), Ι. Boukovinas (GR)
11.00-11.30 Novel Therapeutics and Targeted Therapies in ALK positive NSCLC G. Ioannidis (CY)
11.30-12.00 Advances in treatment of HER2/NTRK/RET/ROS1/BRAF driven NSCLC I. Kornatzis (GR)
12.00-12.30 TKIs in the curative setting M. Kaparelou (GR)
Chairs: O.D. Røe (NOR), A. Boutis (GR)
12.30-13.00 Advances in treatment in malignant mesothelioma I. Metaxas (SUI)
13.00-13.30 Implementation of targeted therapies and immunotherapy in the treatment of thymic malignancies S. Gennatas (UK)
Light Lunch
Advances in targeted therapies & new targets: Current or Future Research Projects Moderators: F. Dimitrakopoulos(GR), G. Ioannidis (CY)
15.00-15.15 Neuropilin 2, new applications for an old target Α. Dimou (US)
15.15-15.30 Deciphering immune infiltration in non-small cell lung carcinomas I. Pateras (GR)
15.30-15.45 PD-L1 expression in CTCs from Lung cancer patients G. Kallergi (GR)
Chairs: Α. Psyrri, D. Papadatos-Pastos (UK)
15.45-16.10 Incorporating functional genomics in the treatment of NSCLC G. Vasmatzis (US)
16.10-16.35 The Evolution of Metastases in NSCLC M. Al Bakir (UK)
16.35-17.00 The immune contexture and immunity in NSCLC A . Giatromanolaki (GR)
17.00-17.25 Combine radiotherapy with immunotherpay M. Koukourakis (GR)
Coffee Break
Chairs: A. Dimou (US), F. Koinis (GR)
17.45-18.15 SCLC Subgroups and Their Potential Clinical Significance F.I. Dimitrakopoulos (GR)
18.15-18.45 Current Strategies in ES-SCLC in the Frontline G. Imseeh (UK)
18.45-19.15 Future perspectives in the treatment of SCLC K. Leventakos (US)
Chairs: D. Papadatos-Pastos (UK), F.I. Dimitrakopoulos (GR)
Dissecting and targeting KRAS-mutant NSCLC. F. Skoulidis (US)
Closing Remarks
